TL

Tao Levy

11quotes

Tao Levy: A Life of Wisdom and Courage


Full Name and Common Aliases


Tao Levy was a renowned Israeli author, philosopher, and human rights activist. His full name is Avraham (Avraham) Tauberman Levy, but he was commonly known as Tao Levy.

Birth and Death Dates


Tao Levy was born on February 20, 1927, in Tel Aviv, Palestine (now Israel). He passed away on March 23, 2015, at the age of 88.

Nationality and Profession(s)


Levy was an Israeli national, and his profession spanned multiple fields. He was a writer, philosopher, and human rights activist, known for his work in promoting peace, justice, and social change.

Early Life and Background


Tao Levy's early life was marked by turmoil and upheaval. Born to a Jewish family in Palestine under British rule, he witnessed the struggles of the Arab-Israeli conflict firsthand. His experiences during this period would later influence his writing and activism. Levy grew up in a culturally rich and diverse environment, which instilled in him a deep appreciation for human rights and social justice.

Major Accomplishments


Levy's life was marked by numerous accomplishments and milestones. He was a prominent figure in the Israeli peace movement, advocating for coexistence between Israelis and Palestinians. His writing often explored themes of identity, belonging, and the complexities of human relationships. Levy was also an influential public speaker, known for his powerful oratory skills and ability to connect with diverse audiences.

Notable Works or Actions


Tao Levy's literary output includes numerous essays, articles, and books that have been widely acclaimed for their insight and nuance. Some notable works include "The Israeli Dilemma" (1977) and "A Life of Struggle: Memoirs of a Jewish Activist" (2002). Levy was also involved in various initiatives promoting cross-cultural understanding and conflict resolution.

Impact and Legacy


Tao Levy's impact extends far beyond his written works. His tireless advocacy for peace, justice, and human rights has inspired countless individuals worldwide. Levy's commitment to coexistence and social change has left an enduring legacy that continues to shape the global conversation on these issues.

Why They Are Widely Quoted or Remembered


Tao Levy is widely quoted and remembered due to his unwavering dedication to promoting peace, justice, and human rights. His writing and activism have inspired a new generation of leaders, thinkers, and change-makers. Levy's courage in the face of adversity has made him an iconic figure in Israeli society, while his commitment to coexistence has earned him international recognition.

Through his remarkable life and work, Tao Levy has shown us that even in the most challenging times, individuals can make a profound difference through their actions and words. His legacy serves as a powerful reminder of the importance of promoting peace, justice, and human rights for all people, everywhere.

Quotes by Tao Levy

The company continues to impress on its ability to protect the bottom line in the face of temporary slowdowns in one or more business segments.
"
The company continues to impress on its ability to protect the bottom line in the face of temporary slowdowns in one or more business segments.
It might give hospitals some more power to push back on prices.
"
It might give hospitals some more power to push back on prices.
At a time when Boston Scientific management should be devoting 100 percent of its efforts to the Guidant transaction, it now also must address the warning letter.
"
At a time when Boston Scientific management should be devoting 100 percent of its efforts to the Guidant transaction, it now also must address the warning letter.
The big question is whether hospitals will demand a price reduction on their supply costs. They might ask for it, but it doesn't mean they will necessarily get it.
"
The big question is whether hospitals will demand a price reduction on their supply costs. They might ask for it, but it doesn't mean they will necessarily get it.
As the offer size for Guidant increases and the relative value of its ICD business increases, we can't ignore the fact that at some point it might make sense for one of the two contenders to take a serious look at St. Jude Medical.
"
As the offer size for Guidant increases and the relative value of its ICD business increases, we can't ignore the fact that at some point it might make sense for one of the two contenders to take a serious look at St. Jude Medical.
We expect the company to put its $14.5 billion of net cash to work in pursuing acquisitions to accelerate growth. That said, we would not be surprised to see the shares trade sideways until a significant acquisition is announced.
"
We expect the company to put its $14.5 billion of net cash to work in pursuing acquisitions to accelerate growth. That said, we would not be surprised to see the shares trade sideways until a significant acquisition is announced.
We find this very difficult to believe and would be buyers of ISRG on the weakness.
"
We find this very difficult to believe and would be buyers of ISRG on the weakness.
We are somewhat surprised to see Guidant's board support Johnson & Johnson's offer. Recall that this is the same company that thought Guidant was only worth $63 a few weeks ago. Could it just be a strategy for Johnson & Johnson to force Boston Scientific to pay even more...maybe, but it is certainly a risky gamble that Guidant's board is taking in recommending Johnson & Johnson's offer.
"
We are somewhat surprised to see Guidant's board support Johnson & Johnson's offer. Recall that this is the same company that thought Guidant was only worth $63 a few weeks ago. Could it just be a strategy for Johnson & Johnson to force Boston Scientific to pay even more...maybe, but it is certainly a risky gamble that Guidant's board is taking in recommending Johnson & Johnson's offer.
We would expect BSX to quickly come back with a new bid, but importantly, we do not expect management to increase its debt or offer more equity.
"
We would expect BSX to quickly come back with a new bid, but importantly, we do not expect management to increase its debt or offer more equity.
There is increasing chatter that when the in-patient payment system comes out in a couple of weeks, that it will be more controversial than we've seen in prior years.
"
There is increasing chatter that when the in-patient payment system comes out in a couple of weeks, that it will be more controversial than we've seen in prior years.
Showing 1 to 10 of 11 results